Conformis, Inc. CFMS
Sep 1, 2023, 3:57 PM EDT
52-week range unavailable
- Market cap
- 17.45M
- Revenue (ttm)
- 59.34M
- Profit margin
- -74.18%
- Shares out
- 7.88M
- Forward P/E
- -0.48
- Volume
- 7.08K
- Open
- 2.26
- Previous close
- 2.27
- Day's range
- 2.25 – 2.27
- Beta
- 1.43
- Analysts
- Buy
- Price target
- 50.00 (+2102.6%)
- Earnings date
- Aug 2, 2023
2Y -26.99 (-92.27%)
Key statistics
- Enterprise value
- 5.76M
- PEG ratio
- 0.03
- Price / sales
- 0.29
- Price / book
- 0.37
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- -17.50%
- Free cash flow
- -29.23M
- Total cash
- 37.79M
- Total debt
- 27.13M
- Return on equity
- -67.39%
- Short % of float
- 5.36%
- 50-day average
- 1.46
- 200-day average
- 2.31
Analyst view
Consensus: buy
- Strong buy1
- Buy1
- Hold5
- Sell0
- Strong sell0
Next earnings
Aug 2, 2023
Expected Aug 2, 2023. Consensus EPS estimate -1.28.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Aug 2, 2023 | Jun 1, 2023 | -1.32 | — | — | — |
| May 8, 2023 | Mar 1, 2023 | -1.56 | — | — | — |
| Mar 1, 2023 | Dec 1, 2022 | -1.84 | — | — | — |
| Nov 2, 2022 | Sep 1, 2022 | -1.75 | — | — | — |
| Aug 8, 2022 | Jun 1, 2022 | -2.00 | — | — | — |
| May 4, 2022 | Mar 1, 2022 | -1.75 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| May 9, 2023 | Oppenheimer | down | Outperform | Perform |
| Nov 11, 2022 | Oppenheimer | main | — | Outperform |
| Nov 4, 2021 | Oppenheimer | main | — | Outperform |
| Sep 22, 2021 | Oppenheimer | main | — | Outperform |
| May 12, 2020 | Oppenheimer | main | — | Outperform |
| Apr 2, 2019 | Oppenheimer | main | Outperform | Outperform |
About Conformis, Inc.
Conformis, Inc., a medical technology company, develops, manufactures, and sells patient-specific products and instrumentation. The company offers personalized knee replacement products, including iUni, iDuo, iTotal CR, and iTotal PS, as well as provides iTotal Identity and Identity Imprint knee replacement products. It also offers Conformis Hip System and Cordera hip replacement, which are hip replacement products; and iJigs, a personalized single-use patient-specific instrumentation. The company markets and sells its products to orthopedic surgeons, hospitals, and other medical facilities through sales force, independent sales representatives, and distributors in the United States, Germany, the United Kingdom, Austria, Ireland, Switzerland, Spain, Portugal, the Netherlands, Belgium, the Dutch Antilles, Suriname, Australia, Brazil, the United Arab Emirates, the Sultanate of Oman, Italy, Poland, and other markets. Conformis, Inc. was incorporated in 2004 and is headquartered in Billerica, Massachusetts.
- Sector
- Healthcare
- Industry
- Medical Devices
- Country
- United States
- Website
- conformis.com
News
Scaling a Personalized Portfolio: restor3d Completes Key Initiative Following Conformis Acquisition 
restor3d Completes Acquisition of Conformis 
Independent Proxy Advisory Firm ISS Recommends Conformis Stockholders Vote “FOR” the Pending Merger with restor3d 
ConforMIS (CFMS) Reports Q2 Loss, Tops Revenue Estimates 
Conformis Reports Second Quarter 2023 Financial Results 
CONFORMIS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Conformis, Inc. - CFMS 
Shareholder Alert: Ademi LLP investigates whether Conformis, Inc. has obtained a Fair Price in its transaction with restor3d 
Shareholder Alert: Ademi LLP investigates whether Conformis, Inc. has obtained a Fair Price in its transaction with restor3d 
CFMS Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Conformis, Inc. Is Fair to Shareholders 
Conformis stock nearly doubles in active trading after cash buyout deal with Restor3d
Your note
Sign in to keep a note on CFMS — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ALLDREDGE J. BRENT | Officer | Sale | Jul 28, 2021 | 605,819 |
| AUGUSTI MARK A | Chief Executive Officer | Stock Award(Grant) | Apr 24, 2023 | 2,508,880 |
| BIENKOWSKI CARRIE STRAWBRIDGE | Director | Stock Award(Grant) | May 23, 2022 | 497,707 |
| FALLON KENNETH P III | Director | Stock Award(Grant) | May 23, 2022 | 507,995 |
| FISHETTI GARY P | Director | Stock Award(Grant) | May 23, 2022 | 261,740 |
| HOWE ROBERT S | Chief Financial Officer | Stock Award(Grant) | Apr 24, 2023 | 796,349 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Wasatch Advisors LP | 7.85% | 588,299 | 1.30M | Mar 30, 2023 |
| Stonepine Capital Management, LLC | 5.37% | 402,651 | 891.87K | Mar 30, 2023 |
| Vanguard Group, Inc. (The) | 3.94% | 295,670 | 654.91K | Mar 30, 2023 |
| Renaissance Technologies, LLC | 2.25% | 168,702 | 373.67K | Mar 30, 2023 |
| Blackrock Inc. | 1.60% | 119,684 | 265.10K | Mar 30, 2023 |
| UBS Group AG | 1.55% | 115,831 | 256.56K | Mar 30, 2023 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Wasatch Ultra Growth Fund | 7.27% | 544,713 | 1.21M | Dec 30, 2022 |
| Vanguard Total Stock Market Index Fund | 2.36% | 177,088 | 392.25K | Dec 30, 2022 |
| Vanguard Extended Market Index Fund | 1.40% | 104,898 | 232.35K | Dec 30, 2022 |
| Fidelity Extended Market Index Fund | 0.50% | 37,575 | 83.23K | Feb 27, 2023 |
| Fidelity Total Market Index Fund | 0.16% | 11,744 | 26.01K | Feb 27, 2023 |
| Dimensional ETF Tr-Dimensional U.S. Targeted Value ETF | 0.14% | 10,719 | 23.74K | Jan 30, 2023 |